

and what we still need to learn. *Sleep Med Rev* 2002; 6: 97–111.

5. Ohayon MM. Observation of the natural evolution of insomnia in the american general population cohort. *Sleep Med Clin* 2009; 4: 87–92.

6. Ellis JG, Perlis ML, Neale LF, Espie CA, Bastien CH. The natural history of insomnia: focus on prevalence and incidence of acute insomnia. *J Psychiatr Res* 2012; 46: 1278–1285.

7. Pretl M. Hypnotika v léčbě nespavosti. *Neurol. pro praxi* 2008; 9: 160–164.

8. Morphy H, Dunn KM, Lewis M, Boardman HF, Croft PR. Epidemiology of insomnia: a longitudinal study in a UK population. *Sleep* 2007; 30: 274–280.

9. Budhiraja R, Roth T, Hudgel DW, et al. Prevalence and polysomnographic correlates of insomnia comorbid with medical disorders. *Sleep* 2011; 34: 859–867.

10. Matheson E, Hainer BL. Insomnia: Pharmacologic Therapy. *Am Fam Physician* 2017; 96: 29–35.

11. Bertisch SM, Herzog SJ, Winkelman JW, Buettner C. National use of prescription medications for insomnia: NHANES 1999–2010. *Sleep* 2014; 37: 343–349.

12. Riemann D, Baglioni C, Bassetti C, et al. European guideline for the diagnosis and treatment of insomnia. *J Sleep Res.* 2017; 26(6): 675–700.

13. Lie JD, Tu KN, Shen DD, Wong BM. Pharmacological Tre-

atment of Insomnia. *PT* 2015; 40: 759–768.

14. Food and Drug Administration FDA drug safety communication: risk of next-morning impairment after use of insomnia drugs; FDA requires lower recommended doses for certain drugs containing zolpidem (Ambien, Ambien CR, Edluar, and Zolpimist) 2013. Dostupné na <http://www.fda.gov/drugs/drugsafety/ucm334033.htm>

15. Walsh JK, Coulouvrat C, Hajak G, et al. Nighttime insomnia symptoms and perceived health in the America Insomnia Survey (AIS) *Sleep* 2011; 34: 997–1011.

16. Zammit GK, Corser B, Doghramji K, et al. Sleep and residual sedation after administration of zaleplon, zolpidem, and placebo during experimental middle-of-the-night awakening. *J Clin Sleep Med* 2006; 2: 417–423.

17. Lunesta (eszopiclone tablets) prescribing information. Marlborough, Massachusetts: Sunovion Pharmaceuticals Inc.; 2014. Dostupné na: <http://www.lunesta.com/PostedApprovedLabeling-Text.pdf>

18. Krystal AD, Huang H, Zummo J, et al. A WASO sub-group analysis of a 6-month study of eszopiclone 3 mg. *Sleep Med* 2012; 13: 691–696.

19. Rozerem (ramelteon tablets) prescribing information. Deerfield, Illinois: Takeda Pharmaceuticals America Inc.; 2010. Dostupné na: <http://general.takedapharm.com/content/file.aspx?filetypecode=rozerempi&cacheRandomizer=15ac1d-c2-362c-4f72-b98a-5a334d7a2545>

20. Almeida Montes LG, Ontiveros Uribe MP, Cortés Sotres J, et al. Treatment of primary insomnia with melatonin: a double-blind, placebo-controlled, crossover study. *J Psychiatry Neurosci* 2003; 28: 191–196.

21. Roth T, Rogowski R, Hull S, et al. Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in adults with primary insomnia. *Sleep* 2007; 30: 1555–1561.

22. Silenor (doxepin tablets) prescribing information. Morristown, New Jersey: Pernix Therapeutics; 2010. Dostupné na: <https://www.silenor.com/Content/pdf/prescribing-information.pdf>

23. Yeung WF, Chung KF, Yung KP, Ng TH. Doxepin for insomnia: a systematic review of randomized placebo-controlled trials. *Sleep Med Rev* 2015; 19: 75–83.

24. Food and Drug Administration FDA approves new type of sleep drug, Belsomra. Dostupné na: <http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm409950.htm>

25. Belsomra (suvorexant tablets) prescribing information. White-house Station, New Jersey: Merck & Co., Inc. Dostupné na: https://www.merck.com/product/usa/pi_circulars/b/belsomra/belsomra_pi.pdf